After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's non-opioid pain relief drug, Journavx, received FDA approval on Jan. 30. The drug is ...
11h
Stocktwits on MSNVertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays BullishShares of Vertex Pharmaceuticals, Inc. were in the spotlight in premarket trading Tuesday as the biotech company received ...
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the strategy for ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
The US Food and Drug Administration (FDA) has approved a non-opioid drug for severe post-surgical pain, which could “redefine ...
SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...
A new non-opioid painkiller, suzetrigine, has just been approved by the US drug regulator, the FDA. It is the first ...
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results